[en] OBJECTIVE: Screening studies have established genetic risk profiles for diseases such as multiple endocrine neoplasia type 1 (MEN1) and pheochromocytoma-paraganglioma (PPGL). Founder effects play an important role in regional/national epidemiology of endocrine cancers, particularly PPGL. Founder effects in the Netherlands have been described for various diseases, some of which established themselves in South Africa due to Dutch emigration. The role of Dutch founder effects in South Africa have not been explored in PPGL. DESIGN: We performed a single-center study in South Africa of the germline genetic causes of isolated/syndromic neuroendocrine tumors. METHODS: Next-generation panel and multiplex ligand-dependent probe amplification for endocrine neoplasia risk genes. RESULTS: From a group of 13 patients we identified six with PPGL, four with sporadic or familial isolated pituitary adenomas (FIPA), and three with clinical MEN1; genetic variants were identified in 9/13 cases. We identified the Dutch founder exon 3 deletion in SDHB in two apparently-unrelated individuals with distinct ethnic backgrounds that had metastatic PPGL. Asymptomatic carriers with this Dutch founder SDHB exon 3 deletion were also identified. Other PPGL patients had variants in SDHB, SDHD and three MEN1 variants were identified among MEN1 and young-onset pituitary adenoma patients. CONCLUSIONS: This is the first identification of a Dutch founder effect for PPGL in South Africa. Awareness of the presence of this exon 3 SDHB deletion could promote targeted screening at a local level. Insights into PPGL genetics in South Africa could be achieved by studying existing patient databases for Dutch founder mutations in SDHx genes.
Papathomas TG, Suurd DPD, Pacak K, Tischler AS, Vriens MR, Lam AK & de Krijger RR. What have we learned from molecular biology of paragangliomas and pheochromocytomas? Endocrine Pathology 2021 32 134–153. (https://doi.org/10.1007/s12022-020-09658-7)
Schiavi F, Dematte S, Cecchini ME, Taschin E, Bobisse S, Piano A Del, Donner D, Barbareschi M, Manera V, Zovato S, et al. The endemic paraganglioma syndrome type 1: origin, spread, and clinical expression. Journal of Clinical Endocrinology and Metabolism 2012 97 E637–E641. (https://doi.org/10.1210/jc.2011-2597)
Bourdeau I, Grunenwald S, Burnichon N, Khalifa E, Dumas N, Binet MC, Nolet S & Gimenez-Roqueplo AP. A SDHC founder mutation causes paragangliomas (PGLs) in the French Canadians: new insights on the SDHC-related PGL. Journal of Clinical Endocrinology and Metabolism 2016 101 4710–4718. (https://doi.org/10.1210/jc.2016-1665)
Cascón A, Pita G, Burnichon N, Landa I, López-Jiménez E, Montero-Conde C, Leskelä S, Leandro-García LJ, Letón R, Rodríguez-Antona C, et al. Genetics of pheochromocytoma and paraganglioma in Spanish patients. Journal of Clinical Endocrinology and Metabolism 2009 94 1701–1705. (https://doi.org/10.1210/jc.2008-2756)
Martins RG, Nunes JB, Máximo V, Soares P, Peixoto J, Catarino T, Rito T, Soares P, Pereira L, Sobrinho-Simões M, et al. A founder SDHB mutation in Portuguese paraganglioma patients. Endocrine-Related Cancer 2013 20 L23–L26. (https://doi.org/10.1530/ERC-12-0399)
Hensen EF, Siemers MD, Jansen JC, Corssmit EPM, Romijn JA, Tops CMJ, Mey AGL Van Der, Devilee P, Cornelisse CJ, Bayley JP, et al. Mutations in SDHD are the major determinants of the clinical characteristics of Dutch head and neck paraganglioma patients. Clinical Endocrinology 2011 75 650–655. (https://doi.org/10.1111/j.1365-2265.2011.04097.x)
Hensen EF, Duinen N van, Jansen JC, Corssmit EPM, Tops CMJ, Romijn JA, Vriends AHJT, van der Mey AGL, Cornelisse CJ, Devilee P, et al. High prevalence of founder mutations of the succinate dehydrogenase genes in the Netherlands. Clinical Genetics 2012 81 284–288. (https://doi.org/10.1111/j.1399-0004.2011.01653.x)
Bayley JP, Grimbergen AEM, van Bunderen PA, van der Wielen M, Kunst HP, Lenders JW, Jansen JC, Dullaart RPF, Devilee P, Corssmit EP, et al. The first Dutch SDHB founder deletion in paraganglioma-pheochromocytoma patients. BMC Medical Genetics 2009 10 34. (https://doi.org/10.1186/1471-2350-10-34)
Zeegers MPA, Poppel F van, Vlietinck R, Spruijt L & Ostrer H. Founder mutations among the Dutch. European Journal of Human Genetics 2004 12 591–600. (https://doi.org/10.1038/sj.ejhg.5201151)
Bruce-Brand C & Van Wyk AC. Prevalence of succinate dehydrogenase deficiency in paragangliomas and phaeochromocytomas at a tertiary hospital in Cape Town: a retrospective review. Journal of Endocrinology, Metabolism and Diabetes of South Africa 2021 26 9–15. (https://doi.org/1 0.1080/16089677.2020.1838161)
Shone D, Goedhals J & Pearce NE. Malignant paraganglioma in an African patient associated with a succinate dehydrogenase subunit B (SDHB) mutation. South African Journal of Surgery 2018 56 64–66. (https://doi.org/10.17159/2078-5151/2018/V56N2A2391)
Siddiqui N, Seedat F, Bulbulia S, Mtshali NZ, Botha A, Krause A, Daya R & Bayat Z. SDHB-associated paraganglioma syndrome in Africa – a need for greater genetic testing. Journal of the Endocrine Society 2021 5 bvab111. (https://doi.org/10.1210/jendso/bvab111)
Quintana-Murci L, Harmant C, Quach H, Balanovsky O, Zaporozhchenko V, Bormans C, Helden PD van, Hoal EG & Behar DM. Strong maternal Khoisan contribution to the South African coloured population: a case of gender-biased admixture. American Journal of Human Genetics 2010 86 611–620. (https://doi.org/10.1016/j.ajhg.2010.02.014)
Statistics South Africa. Mid year population estimates 2019 (STATISTICAL RELEASE P0302). Pretoria, South Africa: Statistics South Africa, 2019. (available at: https://www.statssa.gov.za/publications/P0302/P03022019.pdf)
Bayley JP, Minderhout I van, Weiss MM, Jansen JC, Oomen PHN, Menko FH, Pasini B, Ferrando B, Wong N, Alpert LC, et al. Mutation analysis of SDHB and SDHC: novel germline mutations in sporadic head and neck paraganglioma and familial paraganglioma and/or pheochromocytoma. BMC Medical Genetics 2006 7 1. (https://doi. org/10.1186/1471-2350-7-1)
Vasilev V, Daly AF, Thiry A, Petrossians P, Fina F, Rostomyan L, Silvy M, Enjalbert A, Barlier A & Beckers A. McCune-Albright syndrome: a detailed pathological and genetic analysis of disease effects in an adult patient. Journal of Clinical Endocrinology and Metabolism 2014 99 E2029–E2038. (https://doi.org/10.1210/jc.2014-1291)
Juhlin CC. Challenges in paragangliomas and pheochromocytomas: from histology to molecular immunohistochemistry. Endocrine Pathology 2021 32 228–244. (https://doi.org/10.1007/s12022-021-09675-0)
Rotimi SO, Rotimi OA & Salhia B. A review of cancer genetics and genomics studies in Africa. Frontiers in Oncology 2020 10 606400. (https://doi.org/10.3389/FONC.2020.606400)
Taschner PEM, Jansen JC, Baysal BE, Bosch A, Rosenberg EH, Bröcker-Vriends AHJT, Mey AGL Van Der, Ommen GJB Van, Cornelisse CJ & Devilee P. Nearly all hereditary paragangliomas in the Netherlands are caused by two founder mutations in the SDHD gene. Genes, Chromosomes and Cancer 2001 31 274–281. (https://doi. org/10.1002/gcc.1144)
Rijken JA, Niemeijer ND, Corssmit EPM, Jonker MA, Leemans CR, Menko FH & Hensen EF. Low penetrance of paraganglioma and pheochromocytoma in an extended kindred with a germline SDHB exon 3 deletion. Clinical Genetics 2016 89 128–132. (https://doi. org/10.1111/cge.12591)
Huddle KR. Phaeochromocytoma in black South Africans – a 30-year audit. South African Medical Journal 2011 101 184–188. (https://doi. org/10.7196/SAMJ.4320)
Nel D, Panieri E, Malherbe F, Steyn R & Cairncross L. Surgery for pheochromocytoma: a single-center review of 60 cases from South Africa. World Journal of Surgery 2020 44 1918–1924. (https://doi. org/10.1007/s00268-020-05420-6)
Lima J, Feijão T, Ferreira da Silva A, Pereira-Castro I, Fernandez-Ballester G, Máximo V, Herrero A, Serrano L, Sobrinho-Simões M & Garcia-Rostan G. High frequency of germline succinate dehydrogenase mutations in sporadic cervical paragangliomas in Northern Spain: mitochondrial succinate dehydrogenase structure-function relationships and clinical-pathological correlations. Journal of Clinical Endocrinology and Metabolism 2007 92 4853–4864. (https://doi. org/10.1210/jc.2007-0640)
Kapoor N, Pai R, Ebenazer A, Sen I, Stephen E, Agarwal S, Paul MJ & Rajaratnam S. Familial carotid body tumors in patients with sdhd mutations: a case series. Endocrine Practice 2012 18 e106–e110. (https://doi.org/10.4158/EP12012.CR)
Brouwers FM, Eisenhofer G, Tao JJ, Kant JA, Adams KT, Linehan WM & Pacak K. High frequency of SDHB germline mutations in patients with malignant catecholamine-producing paragangliomas: implications for genetic testing. Journal of Clinical Endocrinology and Metabolism 2006 91 4505–4509. (https://doi.org/10.1210/jc.2006-0423)
Ghayee HK, Havekes B, Corssmit EPM, Eisenhofer G, Hammes SR, Ahmad Z, Tessnow A, Lazúrová I, Adams KT, Fojo AT, et al. Mediastinal paragangliomas: association with mutations in the succinate dehydrogenase genes and aggressive behavior. Endocrine-Related Cancer 2009 16 291–299. (https://doi.org/10.1677/ERC-08-0214)
Benn DE, Gimenez-Roqueplo AP, Reilly JR, Bertherat J, Burgess J, Byth K, Croxson M, Dahia PL, Elston M, Gimm O, et al. Clinical presentation and penetrance of pheochromocytoma/paraganglioma syndromes. Journal of Clinical Endocrinology and Metabolism 2006 91 827–836. (https://doi.org/10.1210/jc.2005-1862)
Vandeva S, Daly AF, Petrossians P, Zacharieva S & Beckers A. Somatic and germline mutations in the pathogenesis of pituitary adenomas. European Journal of Endocrinology 2019 181 R235–R254. (https://doi. org/10.1530/EJE-19-0602)
Cuny T, Pertuit M, Sahnoun-Fathallah M, Daly A, Occhi G, Odou MF, Tabarin A, Nunes ML, Delemer B, Rohmer V, et al. Genetic analysis in young patients with sporadic pituitary macroadenomas: besides AIP don’t forget MEN1 genetic analysis. European Journal of Endocrinology 2013 168 533–541. (https://doi.org/10.1530/EJE-12-0763)
